BCTX Stock Price, BriaCell Therapeutics . Quote, Chart

Market Summary

USD1.39+0.01

Delayed

0.72%

BCTX Stock Price

View Fullscreen

BCTX RSI Chart

BCTX Valuation

Market Cap

22.2M

Price/Earnings (Trailing)

-1.76

Price/Sales (Trailing)

15.0K

Price/Free Cashflow

-0.71

BCTX Price/Sales (Trailing)

BCTX Profitability

Return on Equity

151.57%

Return on Assets

-103.07%

Free Cashflow Yield

-140.71%

BCTX Fundamentals

BCTX Revenue

Revenue (TTM)

3.1K

BCTX Earnings

Earnings (TTM)

-12.6M

Earnings Growth (Yr)

4.94%

Earnings Growth (Qtr)

-288.19%

Breaking Down BCTX Revenue

Last 7 days

-38.2%

Last 30 days

-35.6%

Last 90 days

-57.0%

How does BCTX drawdown profile look like?

BCTX Financial Health

Current Ratio

2.99

BCTX Investor Care

Shares Dilution (1Y)

2.99%

Diluted EPS (TTM)

-1.68

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	0	0	0	0
2021	0	0	3.1K	0
2020	0	0	0	0
2019	0	0	12.0K	0
2018	0	0	16.0K	0

Get all data in R, Python etc through our Historical Stock Data APIs

Which funds bought or sold BCTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	reduced	-63.48	-311,407	67,679	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-57.02	-69,094	18,381	-%
May 15, 2024	Royal Bank of Canada	reduced	-80.65	-99,000	10,000	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	49.05	-838	2,251	-%
May 15, 2024	SABBY MANAGEMENT, LLC	new	-	97,875,000	97,875,000	0.06%
May 15, 2024	ARMISTICE CAPITAL, LLC	unchanged	-	-427,500	510,000	0.01%
May 15, 2024	Atom Investors LP	sold off	-100	-64,186	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	1.12	-52,647	51,477	-%
May 13, 2024	BANK OF MONTREAL /CAN/	added	148	201,954	520,526	-%
May 13, 2024	NATIONAL BANK OF CANADA /FI/	unchanged	-	-23,250	16,725	-%

Are Funds Buying or Selling BCTX?

Are funds buying BCTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BCTX

No. of Funds

Recent SEC filings of BriaCell Therapeutics Corp.

View All Filings

Date Filed	Form Type	Document
May 17, 2024	8-K	Current Report
May 16, 2024	424B5	Prospectus Filed
Apr 02, 2024	8-K	Current Report
Mar 18, 2024	10-Q	Quarterly Report

BriaCell Therapeutics Corp. News

Latest updates

BriaCell Therapeutics Corp. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q3
Revenue	197.9%	36.00	12.00	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	13.1%	4,123	3,647	2,285	1,596	4,807	190	-	-	-	1,879	-	-	-
S&GA Expenses	-4.3%	1,854	1,939	1,409	1,018	3,681	25.00	-	-	-	663	-	-	-
R&D Expenses	32.8%	2,269	1,708	876	581	1,125	166	-	-	-	1,216	-	-	-
Interest Expenses	-	-	-	979*	-45.37	62.00	46.00	-	-	-	639*	-	-	-
Net Income	-189.7%	-10,015	11,161	-27,533	-2,720	2,950	-235	-	-	-	-1,882	-	-	-
Net Income Margin	-80.3%	-9.24	-5.13	-8.75	-4.39	-411.88*	-411.88*	-411.88*	-411.88*	-392.60*	-392.60*	-392.60*	-	-
Free Cashflow	-88.7%	-4,823	-2,556	-1,778	-1,945	-5,587	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q3
Assets	-34.3%	12,231	18,619	27,164	29,722	34,161	38,450	42,577	46,461	48,554	53,299	58,044	46,524	35,004	23,484	11,964	445
Current Assets	-36.2%	11,742	18,408	26,949	29,503	33,939	38,224	42,347	46,227	48,316	-	57,798	-	274	-	261	169
Cash Equivalents	-54.2%	6,245	13,646	21,251	28,170	33,500	37,452	41,042	44,527	47,982	-	57,269	20,064	6.00	-	21.00	157
Current Liabilities	275.0%	3,924	1,047	1,801	1,383	670	974	941	366	605	-	557	-	4,919	-	3,964	1,392
Shareholder's Equity	-430.5%	-8,317	2,516	-3,777	-	-1,280	10,334	10,329	9,958	16,426	1,584	27,672	14,485	-	-	-	-
Retained Earnings	-15.1%	-85,945	-74,650	-80,652	-78,233	-73,338	-61,456	-60,349	-27,582	-22,758	-	-29,141	-	-23,028	-	-22,326	-14,746
Additional Paid-In Capital	-100.0%	-	7,919	7,422	6,888	6,607	6,340	5,228	-	-	-	2,178	-	-	-	-	-
Shares Outstanding	0%	15,982	15,982	15,982	15,518	15,518	15,518	15,518	15,359	15,547	15,239	15,270	-	-	-	-	-
Minority Interest	-19.2%	-244	-205	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q3
Cashflow From Operations	2.7%	-7,401	-7,605	-10,919	-5,331	-3,951	-3,542	-3,325	-4,823	-2,556	-1,778	-1,945	-5,587	-	-	-	-	-	-	-	-
Share Based Compensation	-6.3%	500	534	534	281	267	1,112	878	864	815	518	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	-	-	-	4,000	2.00	-	-47.29	-159	1,369	-	-	38,294	26,462	-	-	-	-	-	-	-	-
Buy Backs	-	-	-	-	-	-	47.00	-	-	9,098	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BCTX Income Statement

2024-01-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2024	Jan. 31, 2023
Operating Expenses:
Research and development expenses	$ 8,257,455	$ 3,053,357	$ 15,114,712	$ 6,308,572
General and administrative expenses	1,571,991	1,432,966	3,217,762	3,580,902
Total operating expenses	9,829,446	4,486,323	18,332,474	9,889,474
Operating loss	(9,829,446)	(4,486,323)	(18,332,474)	(9,889,474)
Financial expenses, net	(1,486,119)	(7,395,439)	12,975,781	(3,098,829)
Share of loss on equity investment	(18,345)		(18,345)
Net loss for the period	(11,333,910)	(11,881,762)	(5,375,038)	(12,988,303)
Net loss attributable to non-controlling interest	(39,307)		(81,978)
Net loss and Comprehensive loss for the period attributable to BriaCell	$ (11,294,603)	$ (11,881,762)	$ (5,293,060)	$ (12,988,303)
Net loss per share attributable to BriaCell - basic	$ (0.71)	$ (0.77)	$ (0.33)	$ (0.84)
Net loss per share attributable to BriaCell - diluted	$ (0.71)	$ (0.77)	$ (0.33)	$ (0.84)
Weighted average number of shares used in computing net basic earnings per share of common stock	15,981,726	15,518,018	15,981,726	15,518,018
Weighted average number of shares used in computing net diluted earnings per share of common stock	15,981,726	15,518,018	15,981,726	15,518,018

BCTX Balance Sheet

2024-01-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jan. 31, 2024	Jul. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 6,244,528	$ 21,251,092
Amounts receivable	30,145	18,873
Prepaid expenses	5,467,286	5,678,542
Total current assets	11,741,959	26,948,507
NON-CURRENT ASSETS:
Investments	2	2
Equity investment in BC Therapeutics	281,655
Intangible assets, net	207,431	215,068
Total non-current assets	489,088	215,070
Total assets	12,231,047	27,163,577
CURRENT LIABILITIES:
Trade payables	3,711,455	1,123,739
Accrued expenses and other payables	212,870	677,718
Total current liabilities	3,924,325	1,801,457
NON-CURRENT LIABILITIES:
Warrant liability	16,624,177	29,139,301
Total non-current liabilities	16,624,177	29,139,301
SHAREHOLDERS’ DEFICIT:
Share Capital of no par value - Authorized: unlimited at January 31, 2024 and July 31, 2023, Issued and outstanding: 15,981,726 shares January 31, 2024 and July 31, 2023, respectively	69,591,784	69,591,784
Share-based payment reserve	8,419,154	7,421,950
Accumulated other comprehensive loss	(138,684)	(138,684)
Non-controlling Interest	(244,418)
Accumulated deficit	(85,945,291)	(80,652,231)
Total shareholders’ deficit	(8,317,455)	(3,777,181)
Total liabilities and shareholders’ deficit	$ 12,231,047	$ 27,163,577

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

0

CEO	Dr. William V. Williams M.D.
WEBSITE	briacell.com
INDUSTRY	Biotechnology

BriaCell Therapeutics Corp. Frequently Asked Questions

What is the ticker symbol for BriaCell Therapeutics Corp.? What does BCTX stand for in stocks?

BCTX is the stock ticker symbol of BriaCell Therapeutics Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BriaCell Therapeutics Corp. (BCTX)?

As of Fri May 17 2024, market cap of BriaCell Therapeutics Corp. is 22.21 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BCTX stock?

You can check BCTX's fair value in chart for subscribers.

What is the fair value of BCTX stock?

You can check BCTX's fair value in chart for subscribers. The fair value of BriaCell Therapeutics Corp. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BriaCell Therapeutics Corp. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BCTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BriaCell Therapeutics Corp. a good stock to buy?

The fair value guage provides a quick view whether BCTX is over valued or under valued. Whether BriaCell Therapeutics Corp. is cheap or expensive depends on the assumptions which impact BriaCell Therapeutics Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BCTX.

What is BriaCell Therapeutics Corp.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, BCTX's PE ratio (Price to Earnings) is -1.76 and Price to Sales (PS) ratio is 14.97 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BCTX PE ratio will change depending on the future growth rate expectations of investors.